Dr. Zoda brings nearly 30 years of clinical research industry experience to CRC. Most of his career has been dedicated to the CNS clinical research space through a variety of roles in operations, business development, and executive leadership. Notably, Dr. Zoda was the Executive Vice President and General Manager for the CNS Business Unit at INC Research/Syneos Health during their exponential growth over the last decade. Prior, he enjoyed a long tenure at PPD in a variety of operations and executive roles. Most recently, Dr. Zoda served as COO for Apex Innovative Sciences and CenExel Clinical Research, both CNS-focused clinical research site networks.

Dr. Hochadel has 30+ years of experience in the planning, managing, and conducting of clinical research trials. His Phase I clinical experience includes multiple dose studies in healthy elderly subjects, tyramine challenge pressor tests, and extensive evaluations of novel delivery systems (e.g. transdermal, nasal, and pulmonary delivery systems) including pharmacokinetic and wearability assessments.

His expertise in Phase II-IV development is highlighted by his work in dementia, including 48-week chronic dosing studies in Alzheimer’s disease subjects and nursing home-based studies targeting behavioral signs and symptoms. He also has significant experience with schizophrenia, movement disorders (including Parkinson’s disease, ataxia, and tardive dyskinesia), depression, bipolar disorder, attention deficit/hyperactivity disorder, obsessive-compulsive disorder, and sleep disorder trials. Dr. Hochadel was also responsible for an anti-osteoporosis compound IND and a development program.

Dr. Hochadel was one of the original founders of Cognitive Research Corporation in 2006 initially serving as Chief Operating Officer. His reputation for integrity and expertise in all areas of CNS brought many early clients to CRC, many of who are still working with the company. Dr. Hochadel’s focus on team building and transparent collaborations with sponsors created the foundation of the culture and performance at CRC. He continues to lead the company as President today.

Prior to CRC, Dr. Hochadel was Senior Director of Psychiatry and Neurology with SCIREX Corporation and Director of Clinical Operations (CNS Center) at Covance, Inc. At Covance, he actively managed senior project managers, cross-functional project teams, and all clinical aspects of central nervous system studies. He also served as Director of Clinical Research at Somerset Pharmaceuticals, Inc. for six years, during which he created preclinical-to-post-marketing development plans and regulatory submissions. During his time at Somerset, Dr. Hochadel conducted more than 30 Phase I clinical studies and was the driving force behind multiple IND applications. He also held the role of President of Advanced Research Corporation, where he was responsible for the overall management and financial health of a full-service contract research organization.

Dr. Hochadel earned his Pharm.D. from Mercer University Southern School of Pharmacy in Atlanta, Georgia. He also holds a B.S. degree in natural sciences from the University of South Florida. Dr. Hochadel is a registered pharmacist and participates in international medical missions.

Dr. Kay is the co-founder of Cognitive Research Corporation and currently serves as Chief Scientific Officer. He received his Ph.D. in psychology (neuro-clinical specialty program) from the University of Memphis and completed his psychology internship at the National Naval Medical Center in Bethesda, Maryland.

From 1985 to 1998, Dr. Kay served as Director of the Neuropsychology Division at Georgetown University School of Medicine’s Department of Neurology. He took an active role in teaching, providing clinical services, and conducting research. Notably, his research included efforts to assess higher cortical functions via computerized methods and conducting investigations into the neuropsychological sequelae of HIV infection, head injury, fibromyalgia, diabetes, eosinophilia myalgia syndrome, alcoholism, and normal aging.

He is the author and publisher of CogScreen, a computerized cognitive test battery used in pharmaceutical research and in clinical practice. He is recognized globally as an expert in the use of driving simulation to assess the impact of drugs on driving performance.

Dr. Kay established the Washington Neuropsychological Institute in 1998. The firm conducted contract research and provided consultation to federal agencies such as the Federal Aviation Administration, the Department of Justice, and the Social Security Administration.

Dr. Kay served as Principal Investigator on single and multi-center clinical drug trials investigating the effects of medication on cognition, mood, and psychomotor performance. He played a key role in studies investigating changes in cognition associated with sedating antihistamines, hormone replacement therapy, stimulant medications, anticholinergics, and nutritional supplements.

Dr. Kay has been invited to speak at professional meetings around the world and has been a speaker and author for the National Academy of Sciences. He has testified before U.S. congressional committees, at FDA hearings, and has served as a consultant for numerous governmental, corporate, and medical organizations. He is the co-author of Aeromedical Psychology, has written several book chapters, and authored numerous peer-reviewed articles that have appeared in Archives of Internal Medicine, American Psychologist, Human Psychopharmacology, British Journal of Pharmacology, Aviation Space and Environmental Medicine, Annals of Allergy, and the American Journal of Managed Care.

Dr. Kay is a diplomate of the American Board of Professional Neuropsychology and the American Board of Assessment Psychology. He is an Associate Professor of Neurology at Georgetown University, a Fellow of the National Academy of Neuropsychologists, and a member of both the International Neuropsychological Society and the American Psychological Association.

Dr. Finman earned a B.S. in Statistics from the State University of New York at Oneonta and a Ph.D. in Biostatistics from the Medical College of Virginia/Virginia Commonwealth University School of Medicine. His 35+ years of experience in drug development spans clinical trial design, conduct reporting, oversight, and defense of regulatory submissions.

Dr. Finman spent 24 years at Pfizer earning additional responsibilities and building his reputation as a trusted and respected statistician with experience in the oversight of clinical statistics, statistical programming, data management, and project managers in the Biometrics department.

Dr. Finman’s clinical trial experience spans Phase I to Phase III and through registration across a broad range of therapeutic areas and indications, for numerous NDA submissions that resulted in FDA approval, including applications for in-license and co-development submissions.

In 2009, Dr. Finman founded Jupiter Point Pharma Consulting, LLC. The firm provided statistical input for drug development programs, including the design, analysis, interpretation, and defense of clinical trials in support of regulatory submission for a wide variety of programs and companies around the world. As part of a long-standing collaboration with CRC (prior to his role as Chief of Biostatistics), Dr. Finman also has expertise in the design and analysis of driving studies using CRC’s customized driving simulator. The firm was acquired by Cognitive Research Corporation in 2022.

In addition to providing oversight for the Statistics and Statistical Programming groups at CRC, he provides technical statistical support for sponsor organizations in the planning, execution, and analysis of clinical studies and development programs. He routinely provides strategic support for regulatory interactions and participates in meetings with sponsors and regulatory agencies, including sponsor representation in FDA Advisory Committee Meetings. He also has considerable experience serving on and in chartering Safety Review Committees and Data Safety Monitoring Boards.

He is a board member of Hope in Focus, a nonprofit patient advocacy organization dedicated to generating awareness, raising funds for research, and providing support, education, and outreach to the Leber Congenital Amaurosis and rare inherited retinal disease community. He is also a member of the American Statistical Association and the International Society for CNS Clinical Trials and Methodology.

When he can find the time, Dr. Finman enjoys boating, playing the piano, and woodworking.